Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298464 · ClinicalTrials.gov registry record · Phase 1
Study of NGM313 in Obese Participants
A Phase 1 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03298464 is a Phase 1 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT03298464, a Phase 1 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants
Interventions
- DRUG Pioglitazone
- BIOLOGICAL NGM313
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03298464
The ClinicalTrials.gov registry entry for NCT03298464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT03298464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03298464 about?
NCT03298464 is a clinical study titled "Study of NGM313 in Obese Participants". The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants
What is the current status of trial NCT03298464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-09-11. Estimated completion is 2018-07-17.
What interventions are being tested in trial NCT03298464?
The interventions under investigation include: Pioglitazone (DRUG), NGM313 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03298464?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.